GSA Capital Partners’s TScan Therapeutics TCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding TCRX
LCM
BBA
DF
GSA Capital Partners's TCRX Position: Q3 2026 in Review
GSA Capital Partners reduced its TScan Therapeutics (TCRX) stake by 6.8% in Q3 2026, selling an estimated $25.8K and leaving 510,700 shares worth $161K. The position accounts for 0.01% of the portfolio, ranked #1640.
GSA Capital Partners first reported a position in TCRX in Q1 2025 and has held it in 5 quarters since. The position peaked at $537K in Q2 2026. 52 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.
- GSA Capital Partners held 510,700 shares of TScan Therapeutics worth $161K as of Q3 2026.
- GSA Capital Partners sold 37,387 TScan Therapeutics shares in Q3 2026, an estimated $25.8K.
- TScan Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1640 holding.
- GSA Capital Partners first reported a position in TScan Therapeutics in Q1 2025 and has held it in 5 quarters since.
- GSA Capital Partners's TScan Therapeutics position peaked at $537K in Q2 2026.
- 52 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.